Fresh analysis indicates that individuals who stop using popular slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who halt conventional diet and exercise regimens.
Published data in a major medical journal points out that while obese individuals often shed a large proportion of their body weight while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"Individuals purchasing these medications need to be cognizant of the danger of rapid rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery implies a return to original weight within about one and a half years.
Comparing Treatments
The analysis, which reviewed dozens of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with older methods.
The team point out that individuals who shed pounds through diet and exercise usually see a more gradual weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Nutrition scientists believe the way of the injections is key to understanding the heightened weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 levels far above than normal may cause the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making excessive eating much more probable."
A Chronic Issue?
The NHS recommend the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals argue that, given the significant potential of weight regain, the therapy is often life-long.
This view is supported by pharmaceutical companies, who state that the results "underscore the persistent character of obesity," comparing it to managing conditions like diabetes.
Patient Testimonies
People who have stopped the medication describe a intense resurgence of hunger.
"It felt as if a trigger activating and you become extremely hungry," described a patient.
This difficulty is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy.
Widespread Use
Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Use is more common among females than males.
- The middle-aged age group shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Finally, researchers caution that while GLP-1 drugs are potent agents for weight loss, they are not a permanent solution and lasting health benefits hinges on combined lifestyle management.
